220 related articles for article (PubMed ID: 24007709)
1. Cost-effectiveness of the management of rh-negative pregnant women.
Duplantie J; Gonzales OM; Bois A; Nshimyumukiza L; Gekas J; Bujold E; Morin V; Vallée M; Giguère Y; Gagné C; Rousseau F; Reinharz D
J Obstet Gynaecol Can; 2013 Aug; 35(8):730-740. PubMed ID: 24007709
[TBL] [Abstract][Full Text] [Related]
2. Is the management of Rh-Rh incompatibility with noninvasive fetal Rh genotyping for targeted prophylaxis cost-effective in the Turkish population?
Demirel E; Kelekçi S; Ekmekci E; Şengül M; İri R; Atasever M
Turk J Med Sci; 2018 Feb; 48(1):1-4. PubMed ID: 29479934
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
[TBL] [Abstract][Full Text] [Related]
4. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Rh alloimmunization.
Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
7. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Hawk AF; Chang EY; Shields SM; Simpson KN
Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
[TBL] [Abstract][Full Text] [Related]
8. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
[TBL] [Abstract][Full Text] [Related]
9. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
[TBL] [Abstract][Full Text] [Related]
10. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
11. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
Szczepura A; Osipenko L; Freeman K
BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
[TBL] [Abstract][Full Text] [Related]
12. Rh(O)D immune globulin products for prevention of alloimmunization during pregnancy.
Aitken SL; Tichy EM
Am J Health Syst Pharm; 2015 Feb; 72(4):267-76. PubMed ID: 25631833
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.
Gajic-Veljanoski O; Li C; Schaink AK; Guo J; Shehata N; Charames GS; de Vrijer B; Clarke G; Pechlivanoglou P; Okun N; Kandel R; Dooley J; Higgins C; Ng V; Sikich N
Transfusion; 2022 May; 62(5):1089-1102. PubMed ID: 35170037
[TBL] [Abstract][Full Text] [Related]
14. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action.
Visser GHA; Di Renzo GC; Spitalnik SL;
Am J Obstet Gynecol; 2019 Sep; 221(3):227.e1-227.e4. PubMed ID: 31121145
[TBL] [Abstract][Full Text] [Related]
15. Guideline No. 448: Prevention of Rh D Alloimmunization.
Fung-Kee-Fung K; Wong K; Walsh J; Hamel C; Clarke G
J Obstet Gynaecol Can; 2024 Apr; 46(4):102449. PubMed ID: 38553007
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of Rh (D) alloimmunization in Rh (D) negative women in pregnancy and after birth of Rh (D) positive infant].
L'ubuský M; Procházka M; Krejcová L; Vetr M; Santavý J; Kudela M
Ceska Gynekol; 2006 May; 71(3):173-9. PubMed ID: 16768042
[TBL] [Abstract][Full Text] [Related]
17. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation.
Crowther CA; Middleton P; McBain RD
Cochrane Database Syst Rev; 2013 Feb; (2):CD000020. PubMed ID: 23450526
[TBL] [Abstract][Full Text] [Related]
18. A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant.
Jones ML; Wray J; Wight J; Chilcott J; Forman K; Tappenden P; Beverley C
BJOG; 2004 Sep; 111(9):892-902. PubMed ID: 15327601
[No Abstract] [Full Text] [Related]
19. High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation.
Saramago P; Yang H; Llewellyn A; Walker R; Harden M; Palmer S; Griffin S; Simmonds M
Health Technol Assess; 2018 Mar; 22(13):1-172. PubMed ID: 29580376
[TBL] [Abstract][Full Text] [Related]
20. Management of rhesus alloimmunization in pregnancy.
Moise KJ
Obstet Gynecol; 2008 Jul; 112(1):164-76. PubMed ID: 18591322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
